Wells Fargo analyst Mohit Bansal lowered the firm’s price target on BioNTech (BNTX) to $150 from $170 to reflect Bristol Myers (BMY), while keeping an Overweight rating on the shares. The firm notes several oncology updates are expected this year, including BNT327 dose optimization data gating Phase 3 starts and first adjuvant setting readout for the personalized cancer vaccine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech’s Strategic Oncology Focus and Strong Financials Drive Buy Rating
- BioNTech’s Strategic Moves and Financial Outlook
- BioNTech price target raised to $134 from $126 at BofA
- BioNTech SE: Strategic Growth and Innovation in Oncology Amidst Strong Financial Foundation
- Cautious Hold on BioNTech SE Amid Revenue Uncertainty and Competitive Challenges